Drug name - Seysara
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8318706 | ALMIRALL | Substituted tetracycline compounds |
May, 2031
(8 years from now) | |
| US9255068 | ALMIRALL | Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same |
Feb, 2033
(10 years from now) | |
| EP2450347B1 | ALMIRALL | Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections |
Dec, 2027
(5 years from now) | |
| EP2450347A1 | ALMIRALL | Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections |
Dec, 2027
(5 years from now) | |
| EP2109602B1 | ALMIRALL | Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections |
Dec, 2027
(5 years from now) | |
| EP2109602A2 | ALMIRALL | Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections |
Dec, 2027
(5 years from now) | |
| EP2455367A1 | ALMIRALL | Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections |
Dec, 2027
(5 years from now) | |
| EP2455367B1 | ALMIRALL | Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections |
Dec, 2027
(5 years from now) | |
| EP2707003A1 | ALMIRALL | Crystalline Salts Of (4S,4As,5Ar,12As)-4-Dimethylamino-3,10,12,12A-Tetrahydroxy-7-[(Methoxy(Methyl)Amino)-Methyl]-1,11-Dioxo-1,4,4A,5,5A,6,11,12A-Octahydro-Naphthacene-2-Carboxylic Acid Amide And Methods Of Using The Same |
May, 2032
(9 years from now) | |
| EP2707003B1 | ALMIRALL | Crystalline Salts Of (4S,4As,5Ar,12As)-4-Dimethylamino-3,10,12,12A-Tetrahydroxy-7-[(Methoxy(Methyl)Amino)-Methyl]-1,11-Dioxo-1,4,4A,5,5A,6,11,12A-Octahydro-Naphthacene-2-Carboxylic Acid Amide And Methods Of Using The Same |
May, 2032
(9 years from now) | |
| EP2707003A4 | ALMIRALL | Crystalline Salts Of (4S,4As,5Ar,12As)-4-Dimethylamino-3,10,12,12A-Tetrahydroxy-7-[(Methoxy(Methyl)Amino)-Methyl]-1,11-Dioxo-1,4,4A,5,5A,6,11,12A-Octahydro-Naphthacene-2-Carboxylic Acid Amide And Methods Of Using The Same |
May, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9481639 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Aug, 2028
(5 years from now) | |
| US8513223 | ALMIRALL | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
Dec, 2029
(7 years from now) | |
Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient
Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg or 150 mg equivalent doses; A method for treating a patient 9 years of age and older suffering from an inflammatory skin disorder of non-nodular moderate to severe acne vulgaris comprising administering an effective amount of sarecycline hydrochloride
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 60MG BASE | TABLET;ORAL | Prescription |
| EQ 100MG BASE | TABLET;ORAL | Prescription |
| EQ 150MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.